Abstracts tagged "meta-analysis"

Abstract Number: 1464 • ACR Convergence 2023
Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis
Omer Pamuk¹, Ansaam Daoud², Loai Dweik³, Niraj Desai⁴ and sarfaraz Hasni⁵, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals, Case Western Reserve University, Akron, OH, ³Cleveland Clinic Akron General, Akron, OH, ⁴Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: End-stage renal disease (ESRD) may develop in up to 20% of patients with lupus nephritis (LN). The SLE disease activity generally declines after the…
Abstract Number: 1465 • ACR Convergence 2023
Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis
Sarah Abi Doumeth¹, Marina Nighat Magrey² and Omer Pamuk³, ¹Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ²Case Western Reserve University, University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: Previous studies have shown that the clinical manifestations of systemic lupus erythematosus (SLE) differ based on age of onset. Late onset SLE has been…
Abstract Number: 1467 • ACR Convergence 2023
Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mariana Gonzalez-Trevino¹, Jeffrey Yang², Larry J. Prokop³, Gabriel Figueroa-Parra¹ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…
Abstract Number: 1509 • ACR Convergence 2023
Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gabriel Figueroa-Parra¹, Maria Cuellar-Gutierrez¹, Mariana Gonzalez-Trevino¹, Larry J. Prokop², M. Hassan Murad³ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ³Evidence-based Practice Center, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding…
Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Mustafa Erdogan¹, Sinem Nihal Esatoglu², Burcak Kilickiran Avci³ and Gulen Hatemi², ¹Marmara University - Pendik Training and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Cardiology, Istanbul, Turkey
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…
Abstract Number: 0207 • ACR Convergence 2023
Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos¹, Fadi Shehadeh², Markos Kalligeros¹ and Eleftherios Mylonakis³, ¹Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, ²Houston Methodist Research Institute, Houston, TX, ³Department of Medicine, Houston Methodist Hospital, Houston, TX
Background/Purpose: Available immunosuppressive treatments for autoimmune inflammatory rheumatic diseases (AIRD) might increase the risk for opportunistic infections, such as Pneumocystis jirovecii pneumonia (PJP). Prophylactic trimethoprim-sulfamethoxazole…
Abstract Number: 1687 • ACR Convergence 2023
Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials
Lihi Eder¹, Sivakami Mylvaganam², Jordi Pardo Pardo³, Jennifer Petkovic⁴, Vibeke Strand⁵, Philip J. Mease⁶ and Keith Colaco⁷, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Department of Biochemistry, University of Toronto, Toronto, ON, Canada, ³Cochrane Musculoskeletal, University of Ottawa, Ottawa, ON, Canada, ⁴Cochrane Equity Methods Group, University of Ottawa, Ottawa, ON, Canada, ⁵Stanford University, Portola Valley, CA, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁷Women’s College Research Institute / Department of Health and Society, University of Toronto, Toronto, ON, Canada
Background/Purpose: Limited information exists on participation and study outcomes by sex in randomized controlled trials (RCTs) among patients with psoriatic arthritis (PsA). Through a systematic…
Abstract Number: 0277 • ACR Convergence 2023
Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis
Julie Sarrand, Dorian Parisis, Muhammad Soyfoo and Paschalis Sidiras, Erasmus Hospital, Brussels, Belgium
Background/Purpose: This is the first systematic review and meta-analysis to examine the prevalence, the diagnostic and the prognostic value of anti-carbamylated protein (CarP) antibodies in…
Abstract Number: 1786 • ACR Convergence 2023
Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis
Lu Bai¹, Chengkai Zhu¹, Yihong Xu², Kunhai Tang¹, Dachun Zhuo¹, Qing Zhang¹, Chengchun Geng¹, Weidong Xu², Hao Wu¹, Xingdong Chen¹ and Jiucun Wang¹, ¹Fudan University, Shanghai, China, ²Changhai Hospital, Shanghai, China
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease of the spinal joints leading to progressive loss of spinal mobility and chronic pain. Gutdysbiosis has been…
Abstract Number: 0335 • ACR Convergence 2023
Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool
Vladislav Tsaltskan¹, Roel Baez² and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²UC San Diego Health, San Diego, CA
Background/Purpose: Recruitment of study participants is challenging and can incur significant costs, particularly for studies of rheumatic disease or other rare conditions. Social media advertising…
Abstract Number: 1806 • ACR Convergence 2023
The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis
Daming Shao¹, Jiyoung Seo¹, Shaunak Mangeshkar¹, Natalia Nazarenko¹, Stepan Esagian¹, Leonidas Palaiodimos¹ and Damianos Kokkinidis², ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Yale University School of Medicine, New Haven, CT
Background/Purpose: Cardiac sarcoidosis (CS) results from granulomatous infiltrating of the myocardium and manifests as an extended clinical spectrum from silence to conduction disturbances, ventricular tachyarrhythmias,…
Abstract Number: 0425 • ACR Convergence 2023
Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Ioasaf Karafotias, Joshua Rothwell, Maryam Adas, Bechman Katie, Mark Russell, Sam Norton and James Galloway, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-bearing B cells and is used to treat Rheumatoid Arthritis (RA). Common Variable Immune Deficiency (CVID) is a primary immune deficiency syndrome…
Abstract Number: 1861 • ACR Convergence 2023
Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Eduardo Santos¹, Bayram Farisogullari², Emma Dures³, Rinie Geenen⁴ and Pedro Machado⁵, ¹Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁴Utrecht University, Vorstenbosch, Netherlands, ⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: To identify the best evidence on the efficacy of non-pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
Abstract Number: 0758 • ACR Convergence 2023
Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease
STEPHANE MITROVIC¹, Arianna De Matteis², Sara Bindoli³, Fabrizio De Benedetti⁴, Bruno Fautrel⁵, Loreto Carmona⁶ and On Behalf Of The Eular/PreS QoC011 Task Force Member⁷, ¹Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, ²IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ³Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, ⁴Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ⁵Sorbonne Université APHP, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) are part of the non-familial (sporadic) systemic inflammatory disorders and are frequently mentioned as…
Abstract Number: 1956 • ACR Convergence 2023
Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis
Lilian Otalora Rojas¹, Karishma Ramsubeik², Luis Sanchez-Ramos², Shastri Motilal³, Jasvinder Singh⁴ and Gurjit S Kaeley⁵, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida, Jacksonville, FL, ³The University of the West Indies, St. Augustine, Trinidad and Tobago, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Autoimmune myositis involves a spectrum of rare autoimmune disorders characterized by inflammation and damage to skeletal muscles. The management of these challenging conditions often…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].